Kyverna Therapeutics to Present Key Neuroimmunology Data at AAN 2026
Event summary
- Kyverna Therapeutics will host a conference call on April 22, 2026, to discuss primary analysis from its KYSA-8 registrational trial of miv-cel in stiff person syndrome (SPS) and longer-term follow-up data from the KYSA-6 Phase 2 trial in generalized myasthenia gravis (gMG).
- Data will be presented at the American Academy of Neurology (AAN) Annual Meeting, held April 18-22, 2026, in Chicago.
- miv-cel is a fully human, autologous, CD19-targeting CAR T-cell therapy designed for potency and tolerability in B-cell-driven autoimmune diseases.
- Kyverna is advancing its neuroimmunology franchise with initial indications in SPS and gMG, with an estimated 6,000 and 80,000 patients diagnosed in the U.S., respectively.
The big picture
Kyverna Therapeutics is positioning itself at the forefront of neuroimmunology with its CAR T-cell therapy, miv-cel. The upcoming data presentations at AAN 2026 are critical for validating the therapy's efficacy and safety in rare autoimmune diseases, potentially reshaping treatment paradigms. The company's focus on SPS and gMG, both with significant unmet medical needs, underscores its strategic aim to capture a niche in the autoimmune disease market. Success in these indications could pave the way for broader applications in other B-cell-driven autoimmune conditions.
What we're watching
- Clinical Efficacy
- How the primary analysis from the KYSA-8 trial will impact the regulatory pathway for miv-cel in stiff person syndrome.
- Market Potential
- Whether the longer-term follow-up data from the KYSA-6 trial will strengthen Kyverna's position in the generalized myasthenia gravis market.
- Strategic Expansion
- The pace at which Kyverna can advance additional clinical and investigator-sponsored studies in multiple sclerosis and rheumatoid arthritis.
Related topics